Rayca Precision utilizes AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, to analyze genomic and transcriptomic data for personalized cancer treatment strategies. The technology addresses the challenge of cancer heterogeneity by providing precise predictions of drug responses and patient outcomes, enabling tailored therapeutic interventions.
Funding
Funding not disclosed
Founders
Product
Problem
Cancer treatment is often hindered by the heterogeneity of tumors and the difficulty in predicting individual patient responses to specific drugs. Analyzing genomic and transcriptomic data to personalize treatment strategies is a complex challenge. Traditional methods struggle to provide precise predictions of drug responses and patient outcomes, limiting the effectiveness of tailored therapeutic interventions.
Solution
Rayca Precision offers AI-driven bioinformatics platforms, OncoCrest™ and RSA2™, designed to analyze genomic and transcriptomic data and provide personalized cancer treatment strategies. OncoCrest™ analyzes transcriptomic sequencing data to provide insights into drug responses, enabling informed decisions for individualized treatment strategies. It utilizes advanced bioinformatics and deep learning to stratify patients based on genetic and molecular traits, revolutionizing treatment planning and paving the way for targeted therapies. RSA2™ automates bioinformatics analysis, empowering users to unravel complex genetic insights and predict 3D protein structures. These platforms bridge research and clinical practice by integrating public and curated datasets, closing the gap between research and clinical practice.
Target Audience
The primary users are clinical scientists, researchers, universities, hospitals, and research initiatives focused on precision oncology, drug discovery, and personalized medicine.
Features
- **OncoCrest™:**
- AI-driven predictions of drug responses based on transcriptomic sequencing data.
- Stratified patient analysis based on genetic and molecular traits.
- Comprehensive survival analysis for informed treatment choices.
- Fusion gene analysis for novel target identification.
- Personalized prognostic insights with survival analysis and cohort comparisons.
- **RSA2™:**
- Automated bioinformatics analysis for complex genetic insights.
- Prediction of 3D protein structures from transcriptomic data.
- Identification of fusion events and their structural impact.
- Integration of RNA-Seq data for fusion protein folding predictions.